New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 24, 2014
08:11 EDTTGTX, LGNDTG completes global license agreement with Ligand for IRAK4
TG Therapeutics (TGTX), announced an agreement with Ligand Pharmaceuticals (LGND) to license exclusive global rights to develop and commercialize Ligand's IRAK4 inhibitor research program. The IRAK4 program is currently in pre-clinical development. Under the terms of the agreement, Ligand will receive an up-front licensing fee of 125k unregistered shares of TG Therapeutics' common stock. In addition, TG will make development and sales-based milestone payments and will pay a tiered, mid-to-high single digit royalty on net sales.
News For TGTX;LGND From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 13, 2015
17:33 EDTTGTXTG Therapeutics to present updated data for TG-1101 at ASCO
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use